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The activation of liver X receptor (LXR) promotes
cholesterol efflux and repression of inflammatory
genes with anti-atherogenic consequences. The
mechanisms underlying the repressive activity of
LXR are controversial and have been attributed to
cholesterol efflux or to transrepression of activator
protein-1 (AP-1) activity. Here, we find that choles-
terol efflux contributes to LXR repression, while
the direct repressive functions of LXR also play a
key role but are independent of AP-1. We use
assay for transposase-accessible chromatin using
sequencing (ATAC-seq) to show that LXR reduces
chromatin accessibility in cis at inflammatory gene
enhancers containing LXR binding sites. Targets
of this repressive activity are associated with leuko-
cyte adhesion and neutrophil migration, and LXR
agonist treatment suppresses neutrophil recruit-
ment in a mouse model of sterile peritonitis. These
studies suggest a model of repression in which li-
ganded LXR binds in cis to canonical nuclear recep-
tor binding sites and represses pro-atherogenic
leukocyte functions in tandem with the induction
of LXR targets mediating cholesterol efflux.INTRODUCTION
Macrophage inflammatory and metabolic processes determine
the progression of several inflammatory diseases, such as
atherosclerosis (Murray andWynn, 2011). During atherogenesis,
macrophages in the artery wall become cholesterol loaded and
produce inflammatory cytokines, leading to leukocyte recruit-
ment and plaque destabilization (Moore and Tabas, 2011). The3774 Cell Reports 25, 3774–3785, December 26, 2018 ª 2018 The A
This is an open access article under the CC BY license (http://creativeliver X receptor (LXR) is a nuclear receptor with two isoforms,
LXRa and LXRb, that respond to oxysterols generated during
cellular cholesterol loading by promoting cholesterol efflux and
inflammatory gene repression (Schulman, 2017). LXR agonists
are potently anti-inflammatory and anti-atherogenic in mouse
models (Joseph et al., 2002, 2003).
Systemic LXR activation leads to induction of hepatic lipogen-
esis, prompting a search for specific anti-atherogenic functions
of LXR that can be dissociated from the hepatotoxic effects of
LXR activators (Schulman, 2017). Thus, it has been reported
that LXR protects from atherogenesis both through induction
of cholesterol efflux transporters and through transrepression
of macrophage inflammatory genes (Kappus et al., 2014).
LXR’s repressive activity has been attributed to the formation
of a complex containing small ubiquitin-like modifier (SUMO)-
modified LXR and the corepressor nuclear corepressor (NCoR)
with affinity for the inflammatory transcription factor activator
protein-1 (AP-1) (Ghisletti et al., 2007, 2009). Alternatively, it
has been reported that LXR SUMOylation and NCoR may be
dispensable for gene repression by LXR, and certain anti-inflam-
matory activities of LXR may reflect the metabolic functions of
LXR targets, including the cholesterol efflux transporter ATP-
binding cassette transporter A1 (ABCA1) (Ito et al., 2015).
Here, we use genetic and pharmacological models to estab-
lish that LXR repression is only partly dependent on cholesterol
efflux and independent of AP-1 transactivation. Rather, based
on studies using RNA sequencing (RNA-seq), assay for transpo-
sase-accessible chromatin using sequencing (ATAC-seq), and
alignment of LXR chromatin immunoprecipitation sequencing
(ChIP-seq) with ATAC-seq data, the direct repressive function
of LXR appears to be mediated through cis-binding of LXR to
enhancer elements, leading to chromatin closure. LXR repres-
sion specifically regulates a subset of genes comprising
chemokines and adhesion molecules involved in regulating
neutrophil migration in the setting of low-grade inflammation.
We demonstrate that LXR agonist treatment attenuates neutro-


























































































































































































Figure 1. Cholesterol Efflux Transporters Partly Mediate LXR Repression
(A)Abca1fl/flAbcg1fl/fl (floxed ctrl) or LysMCre Abca1fl/flAbcg1fl/fl (Mac-ABCDKO) BMDMswere treated for 3 hr with 500 nMT0 before stimulation with 10 ng/mL LPS
for 2 hr.
(legend continued on next page)
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associated with LXR cis-repression and regulation of cholesterol
metabolism in a cell-intrinsic manner. Thus, LXR regulates
inflammation and neutrophil migration through both metabolic
and repressive functions.
RESULTS
Cholesterol Efflux Transporters Partly Mediate LXR
Repression
To study mechanisms of inflammatory gene repression by LXR,
we used bone-marrow-derived macrophages (BMDMs) treated
with the inflammatory Toll-like receptor 4 (TLR4) agonist lipo-
polysaccharide (LPS) and the LXR agonist T0901317 (T0) and
genetically or pharmacologically perturbed potential mediators
of LXR functions. LXR activation by T0 for 3 hr prior to LPS stim-
ulation is associated with repression of the inflammatory genes
Cox2 and Il1b (Figure S1A). This repressive effect of T0 is lost
at high doses of LPS (Figure S1B). T0 activates LXR as well as
FXR and PXR in hepatocytes and ROR-gt in T cells (Houck
et al., 2004; Mitro et al., 2007; Solt et al., 2012). However, the
anti-inflammatory activity of T0 in macrophages is abrogated
by knockout of LXRa and LXRb in macrophages, demonstrating
specificity for LXR (Figure S1A).
We used this model to examine the requirement for LXR tar-
gets in inflammatory gene repression by LXR. The LXR target
ABCA1 has been reported to antagonize TLR4 signaling by inter-
fering with its adaptor protein, MYD88 (Ito et al., 2015). Consis-
tent with earlier studies, we found that knockout of Abca1 and
the related cholesterol efflux transporter Abcg1 in macrophages
partly but significantly attenuates the anti-inflammatory effect of
LXR agonists (Figures 1A and 1B). We used Myd88 knockout
macrophages to assess the requirement for this potential target
of cholesterol depletion in the repressive effect of T0. Knockout
ofMyd88 is associatedwith reduced expression ofCox2 and Il1b
(Figure 1C), which may alter mechanisms of inflammatory gene
induction. With this caveat, we observed repression of Cox2
and Il1b by T0 in these macrophages, suggesting a MYD88-in-
dependent effect (Figure 1C). In sum, cholesterol efflux trans-
porters induced by LXR appear to play a role in LXR repression
in addition to other activities of LXR or LXR targets.
Other LXR targets involved in metabolism, such as lysophos-
phatidylcholine acyltransferase 3 (Lpcat3), stearoyl-CoA desa-
turase 2 (Scd2), and the efferocytosis receptor Mertk, have
also been linked to anti-inflammatory effects in various models
(A-Gonzalez et al., 2009; Li et al., 2013; Rong et al., 2013). We
addressed whether they play a role in LXR repression in macro-
phages using loss-of-function approaches. Knockout of Lpcat3
in macrophages reduces phosphatidylcholine polyunsaturated(B) Data in (A) plotted as percent repression normalized to the extent of LPS-ind
(C) Wild-type (WT) or Myd88/ BMDMs were treated as in (A).
(D) Lpcat3fl/fl (floxed ctrl) or LysMCre Lpcat3fl/fl (Mac-Lpcat3KO) BMDMs were tre
(E) BMDMs were transfected with siSCD2 SMARTpool siRNA or non-targeting s
(F) BMDM were treated with MAPK inhibitors (10 mM PD0325901 and 1 mM BIRB
mRNA expressionwas evaluated by qPCR, andmean ±SEM is plotted. n = 4 biolo
post hoc test (A and C–F) or Student’s t test with Benjamini-Hochbergmultiple tes
control; #p < 0.05, ##p < 0.01, and ###p < 0.001 for alternative genotype; yp
representative of two independent experiments.
See also Figure S1.
3776 Cell Reports 25, 3774–3785, December 26, 2018fatty acid (PUFA) content (Figure S1C) but has no effect on
LXR repression of Cox2 and Il1b (Figure 1D). Likewise, knock-
down of Scd2 by small interfering RNA (siRNA) does not affect
LXR repression (Figures 1E and S1D). MERTK blockade using
a neutralizing antibody approach (Sen et al., 2007) similarly has
no effect on repressive effects of the LXR agonist T0 in macro-
phages (Figure S1E).
These findings suggest a potential role for LXR in direct
repression of inflammatory gene enhancers, as reported in
earlier studies in which LXR was proposed to interfere with
AP-1 transactivation (Ghisletti et al., 2009). Thus, we inhibited
LPS-inducible AP-1 activation using inhibitors of mitogen-acti-
vated protein kinases (MAPKs) (Tong et al., 2016), which phos-
phorylate and activate AP-1 (Kawai and Akira, 2010). MAPK
inhibitor treatment markedly reduces Cox2 and Il1b expression,
consistent with defective AP-1 activation (Figure 1F). With the
caveat that gene expression is markedly reduced in this setting,
Cox2 and Il1b remain LPS inducible and repressed by T0 (Fig-
ure 1F). Together, these observations suggest that direct repres-
sion by LXR may be independent of MAPK and AP-1 signaling,
which is inconsistent with existing mechanistic models (Glass
and Saijo, 2010).
LXR Agonist Closes Chromatin at Inflammatory Gene
Enhancers
To further explore potential mechanisms responsible for LXR
repression of inflammatory genes, we assessed the identity of
gene regulatory elements associated with inflammatory gene
repression using ATAC-seq. ATAC-seq identifies genomic re-
gions susceptible to DNA insertion by Tn5 transposase, and
these regions are associated with gene-regulatory activity
(Buenrostro et al., 2013). Using ATAC-seq, we determined
open chromatin regions in control macrophages or macro-
phages treated with T0, LPS, or both (Table S1). We focused
our analysis on macrophage enhancers, defined by activating
histone marks H3K27ac or H3K4me2 in published primary
macrophageChIP-seq data (Oishi et al., 2017). Enhancer filtering
captured 70% of open chromatin regions and limited our anal-
ysis to regions likely to be involved in macrophage gene expres-
sion (Lavin et al., 2014). Principal component analysis of the
ATAC signal over all macrophage enhancers showed that repli-
cates cluster by condition, establishing the reproducibility of
the assay, with a strong effect of LPS and a moderate effect of
T0 in the first two principal components (Figure S2A).
T0 treatment leads to decreases in chromatin accessibility at
targets of LXR repression, such as Il1b (Figure 2A), andmoderate
increases in chromatin accessibility at LXR targets, such as
Srebf1 (Figure 2B). On a genome-wide basis, T0 treatment isucible gene expression in each genotype.
ated as in (A).
iRNA (siCtrl) for 24 hr, rested for 24 hr, and then treated as in (A).
0796) and then treated as in (A).
gical replicates. Significance was determined by one-way ANOVAwith Tukey’s
ting correction (B). *p < 0.05, **p < 0.01, and ***p < 0.001 for T0 treatment versus




Figure 2. LXR Agonist Closes Chromatin at Inflammatory Gene Enhancers
WTBMDMswere treated for 3 hr with 500 nM T0 before stimulation with 10 ng/mL LPS for 2 hr and harvested for ATAC-seq. Accessible regions were determined
from ATAC-seq data, and analysis was restricted to macrophage H3K4me2- or H3K27ac-marked enhancers defined by Oishi et al. (2017).
(legend continued on next page)
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associated with closure of 6,474 enhancers (‘‘T0-closed’’) and
opening of 224 enhancers (‘‘T0-opened’’) (Figure S2B). We used
Gene Ontology (GO) analysis to assess cellular functions that
may be regulated by each enhancer set by determining the
gene nearest to each enhancer and performing GO analysis
(Thomas et al., 2003) on the corresponding gene set. T0-closed
enhancers are nearest to genes associated with GO categories
related to TLR signaling, positive regulation of T cell activation,
and regulation of phagocytosis, linking the observed chromatin
closure events to LXR’s anti-inflammatory activity (Figure 2C;
Table S2). Sequencemotif analysis of T0-closed enhancers using
HOMER (Heinz et al., 2010) revealed an enrichment for nuclear re-
ceptor half-sitemotifs and direct repeat-4 (DR4) LXR response el-
ements (Figure 2D; Table S3), suggesting that LXR may bind
directly at these enhancers. Analysis of enhancers closed by T0
after LPS treatment (‘‘T0-closed-in-LPS’’), 36% of which overlap
with T0-closed enhancers, confirmed the observed associations
with inflammatory gene GO categories and nuclear receptor
response element motifs (Figures S2C and S2D).
To validate our enhancer identification method, we examined
the effect of LPS treatment. LPS treatment led to the opening of
2,020 enhancers (‘‘LPS-opened’’) and closure of 4,636 enhancers
(‘‘LPS-closed’’) (Figure S2B). Genes nearest to LPS-opened en-
hancers are linked to GO categories related to LPS-mediated
signaling and positive regulation of T cell activation, which are
highly similar to the GO categories of genes nearest to T0-closed
enhancers (Figure 2E; Table S4). HOMER motif analysis of LPS-
opened enhancers revealed a prominent enrichment for nuclear
factor-kB (NF-kB) and AP-1 binding sites (Figure 2F; Table S5),
consistent with previous studies of inflammatory enhancers
(Tong et al., 2016). In untreated or TLR4-stimulated macro-
phages, the ATAC signal correlates strongly with H3K27 acetyla-
tion signal measured in published primary macrophage ChIP-seq
data (Oishi et al., 2017) (r = 0.8 for each condition; Figures S2E
and S2F) and captures 80% of H3K27ac+ peaks, consistent
with prior evidence that chromatin accessibility changes are
linked to histone modification changes involved in transcriptional
regulation (Bell et al., 2011; Mueller et al., 2017).
LXR Binding by ChIP-Seq Localizes at T0-Closed
Enhancers
Motif analysis of T0-closed enhancers suggested that LXR may
bind directly at these sites. To further assess this possibility, we
aligned the LXR ChIP signal from a published dataset (Oishi
et al., 2017) to enhancers closed or opened by T0 from our
ATAC-seq data. In this published LXR ChIP-seq dataset, the
LXR agonist GW3965 was used to activate LXR; the specificity
for LXR binding was established at the level of antibody recogni-
tion of LXR and confirmed by motif enrichment (Oishi et al.,(A and B) Representative genome browser track of chromatin accessibility signal
vehicle or T0 treatment. Signal is plotted in units of reads per genomic content (R
(C) PANTHER GO categories enriched in genes nearest to T0-closed enhancers
(D) HOMER de novomotifs enriched in T0-closed enhancers (p < 13 1012; top 5
nuclear receptor half-site.
(E) PANTHER GO categories enriched in genes nearest to LPS-opened enhance
(F) HOMER de novo motifs enriched in LPS-opened enhancers (p < 1 3 1012; t
See also Figure S2 and Tables S1–S5.
3778 Cell Reports 25, 3774–3785, December 26, 20182017). LXR ChIP peaks are closely aligned with regions where
T0 treatment reduced chromatin accessibility, as at Il1b (Fig-
ure 3A). On a genome-wide basis, the LXR ChIP signal is super-
imposed on T0-closed enhancers, producing a single peak of the
LXR ChIP signal in histograms centered on closed enhancers
(Figure 3B). Plotting the individual LXR ChIP signals for each
enhancer after aligning the enhancer centers showed that LXR
binding is present at many enhancers before LXR activation or
TLR4 stimulation by the agonist Kdo2-lipid A (KLA) and at most
enhancers after LXR or TLR4 stimulation (Figure 3C).
Alignment of LXR ChIP-seq to T0-closed-in-LPS enhancers
revealed that LXR ChIP signal localized to these regions as
well (Figures S3A and S3B). The LXR ChIP signal intensity is
similar between T0-closed and T0-closed-in-LPS enhancers,
suggesting a common mechanism of LXR recruitment in the
presence or absence of inflammatory stimulation. At T0-opened
enhancers, the LXR ChIP signal is similarly enriched (Figures
S3C and S3D), consistent with the established cis-activating ac-
tivity of LXR at enhancers of LXR targets. GW3965 treatment
increased the LXR ChIP signal at enhancers closed by T0 (Fig-
ure 3B), consistent with previous observations that DNA-binding
affinity of LXR is increased with LXR agonist treatment (Pehko-
nen et al., 2012). In combination with the enrichment for LXR
binding sites in T0-closed enhancers, the alignment of LXR
ChIP signal with these sites indicates that LXR binds in cis to en-
hancers of inflammatory genes.
Chromatin Accessibility Changes with T0 Are Linked to
Gene Expression Changes
We used RNA-seq to determine the functional correlates of T0-
associated changes in chromatin accessibility at the level of
gene expression. We treated BMDMs with or without T0 for
3 hr before stimulation with 10 ng/mL LPS for 2 hr, conditions
identical to those in which we established that Cox2 and Il1b
repression by T0 is LXR-dependent. Comparison of genes and
enhancers regulated by T0 revealed that 56% of >1.5-fold
T0-induced genes are associated with a T0-opened or T0-
opened-in-LPS enhancer within 100 kb of the transcription start
site (Figure 4A), while 78% of >1.5-fold T0-repressed genes are
associated with a T0-closed or T0-closed-in-LPS enhancer (Fig-
ure 4B). These associations are significant compared with
randomly selected genes when the enhancer-promoter distance
distributions are systematically compared (Figures 4C and 4D),
as expected based on the association of chromatin accessibility
with gene regulatory activity. Unexpectedly, 81% of T0-induced
genes are also associated with either T0-closed or T0-closed-in-
LPS enhancers (Figure 4B), suggesting that cis-binding of LXRs
near these genes leads to both chromatin opening and closure
events. Thus, the proximity of enhancers regulated by T0 toaround the T0-repressed gene Il1b (A) and the T0-induced gene Srebf1 (B) with
PGC).
(Bonferroni-adjusted p < 0.05).
motifs displayed). FE, fold enrichment; LXRE, LXR response element; NR-half,
rs (Bonferroni-adjusted p < 0.05).
op 5 motifs displayed). n = 4 biological replicates. FE, fold enrichment.
AB
C
Figure 3. LXR Binding by ChIP-Seq Localizes at T0-Closed Enhancers
The LXR ChIP-seq signal from Oishi et al. (2017) was plotted at enhancer sets derived from ATAC-seq of BMDMs treated for 3 hr with 500 nM T0 before
stimulation with 10 ng/mL LPS for 2 hr.
(legend continued on next page)
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T0-induced or T0-repressed genes provides evidence that
the observed accessibility changes correlate with transcriptional
regulation events and supports our observation that LXR binding
leads to chromatin closure at many sites.
LXR Represses Neutrophil Migration Genes
In total, T0 treatment represses 242 genes and induces 170
genes at a false discovery rate (FDR) threshold of 5% (Figure 5A).
More than half of T0-repressed genes (61%) are LPS-inducible
inflammatory genes (Figure 5A). GO analysis showed that
T0-repressed genes are associated with immune-related func-
tions, including regulation of T-helper cell differentiation, leuko-
cyte cell-cell adhesion, chemokine signaling, and granulocyte
chemotaxis (Figure 5B; Table S6). T0-induced genes are associ-
ated with lipoprotein activity and cellular lipid metabolism (Fig-
ure 5C). As the roles of LXR in lipid metabolism and control of
T cell priming are well established (Ito et al., 2016), we investi-
gated the enrichment of multiple GO categories regulating leuko-
cyte and specifically neutrophil migration among T0-repressed
genes. Leukocyte cell-cell adhesion and granulocyte chemo-
taxis genes repressed by T0 include the cytokine Il1b, chemo-
kines, and adhesion molecules, including the beta integrin
gene Itgb2 (Figures 5D and 5E).
LXR Activation Suppresses Neutrophil Migration In Vivo
The repression of genes associated with leukocyte cell-cell
adhesion and granulocyte chemotaxis in inflammatory macro-
phages led us to consider whether LXR activation would block
neutrophil recruitment during sterile inflammation. We used the
yeast cell wall component zymosan A to elicit sterile peritonitis,
which is characterized by infiltration of neutrophils in the onset
phase 4–24 hr after zymosan injection, followed by resolution
over 3 days (Newson et al., 2014). Mice were treated for
3 days with 10 mg/kg T0 by daily oral gavage and given a final
dose 2 hr before intraperitoneal injection of 0.1 mg zymosan
(Figure 6A). Peritoneal exudates were collected 0, 12, and
24 hr after zymosan injection, and peritoneal exudate cells
were identified as neutrophils (Ly6G+) or macrophages (F4/
80+) by flow cytometry.
LXR agonist treatment leads to an overall decrease in perito-
neal exudate cell counts (p < 0.05 by two-way ANOVA;
Figure 6B). This effect is largely driven by a 44% decrease in
neutrophil recruitment during inflammation onset (Figure 6C).
Recruitment of monocyte-derived macrophages starts between
12 and 24 hr after zymosan injection, at which point resident
macrophages are no longer recovered (Bannenberg et al.,
2005), and is unchanged in T0-treated mice when compared to
vehicle-treated controls (Figure 6D). Ly6G- F4/80- peritoneal
exudate cell counts are also unchanged (Figure S4A). Blood
neutrophil counts are unchanged after 3 days of T0 treatment,(A) Representative genome browser track of the LXR ChIP signal around the T0-r
(RPGC).
(B) Histogram of the LXR ChIP-seq signal centered on T0-closed enhancers. LXR-
the LXR agonist GW3965 for 24 hr; LXR-KLA1h, chromatin from TGEMs stimulate
immunoprecipitated with anti-LXR antibody (notr, no treatment).
(C) Heatmap of the LXR ChIP-seq signal as in (B) centered on T0-closed enhanc
n = 4 biological replicates (ATAC-seq) or 1 biological replicate (LXR ChIP-seq). S
3780 Cell Reports 25, 3774–3785, December 26, 2018suggesting that the effect of T0 on exudate neutrophil counts
is a consequence of defective neutrophil recruitment (Fig-
ure S4B). Exudate protein content reflects leakage of plasma
proteins into the peritoneum (Bannenberg et al., 2005) and is un-
changed after T0 treatment (Figure S4C), suggesting a cell-
intrinsic mechanism for the defect in neutrophil recruitment.
The specific defect in neutrophil migration suggests a poten-
tial role for LXR in regulating genes involved in lipid metabolism
or cell adhesion in these cells. Thus, we assayed mRNA from
neutrophil-rich early peritoneal exudates (4 hr after zymosan
administration) and found that the LXR targets Abca1 and
Abcg1 are induced, while the adhesion molecule Itgb2 is
repressed (Figure 6E). Interestingly, we found that Abca1 and
Abcg1 are highly expressed and induced by T0 in isolated
Ly6G+ exudate neutrophils (Figure 6F), suggesting that T0 has
a cell-intrinsic effect on neutrophil cholesterol metabolism.
Expression of Cox2 and Il1b, on the other hand, is unchanged
in peritoneal exudate mRNA, potentially due to the high level of
inflammatory gene expression elicited by zymosan exposure,
which exceeds the level of induction of these genes at which
they are sensitive to LXR repression in vitro, similar to the effects
of high levels of LPS (Figures S4D and S4E). These results sug-
gest that LXR may suppress neutrophil migration through both
metabolic and anti-inflammatory activities.
DISCUSSION
LXR agonists suppress inflammation, which has stimulated
widespread interest in their development as therapeutics for
diseases such as dermatitis, rheumatoid arthritis, and athero-
sclerosis (Joseph et al., 2003; Kappus et al., 2014; Li et al.,
2010). This activity has been linked to either LXR transrepression
or cholesterol efflux, but recent studies have challenged the
role of transrepression by LXR in control of inflammation (Ito
et al., 2015). We confirmed a role for cholesterol efflux in LXR
repression but uncovered a cis-repressive activity of LXR
acting at inflammatory gene enhancers that plays a major role
in LXR repression. We further established that this activity tar-
gets genes associated with several pro-atherogenic leukocyte
functions, including neutrophil migration, and found that LXR
agonist treatment blocks neutrophil recruitment during sterile
inflammation.
The direct repressive effect of LXR agonists has been attrib-
uted to an NCoR-dependent repressive function of SUMOylated
LXR acting generally at the stimulus-dependent transcription
factor AP-1 (Ghisletti et al., 2009). This model suggests that dur-
ing LXR repression, LXR binds indirectly to corepressor com-
plexes around AP-1 response elements without a defined role
for the DNA-binding domain of LXR. In contrast, we find that
the direct repressive activity of LXR is associated with bindingepressed gene Il1b. The signal is plotted in units of reads per genomic content
GW, chromatin from thioglycolate-elicited macrophages (TGEMs) treated with
d with the TLR4 agonist KLA for 1 hr; LXR-notr, chromatin from resting TGEMs
ers.




Figure 4. Chromatin Accessibility Changes with T0 Are Linked to Gene Expression Changes
Transcription start site (TSS) positions of differentially expressed genes in RNA-seq of BMDMs treated with T0 for 3 hr and 10 ng/mL LPS for 2 hr were compared
to positions of enhancers opened or closed by T0 in ATAC-seq data collected from BMDMs in the same conditions.
(A and B) Percentage of genes in T0-induced, T0-repressed, or random genes with an enhancer opened by T0 (A) or closed by T0 (B) in the control or LPS-
stimulated condition within 100 kb of the TSS.
(C and D) Distribution of distances from the TSS to the nearest enhancer for T0-induced, T0-repressed, or random genes to enhancers opened by T0 (C) or closed
by T0 (D) in the control or LPS-stimulated condition.
n = 4 biological replicates (ATAC-seq) or 3 biological replicates (RNA-seq). Significance was determined by Kruskal-Wallis nonparametric one-way ANOVA with
Dunn post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant.in cis to LXR response elements and does not appear to require
AP-1 activity, indicating that LXR repression is targeted by
genome-encoded regulatory interactions to certain inflamma-
tory genes where LXR binds directly. This proposed mechanism
of repression is similar to the cis-repressive activity of the gluco-corticoid receptor (Uhlenhaut et al., 2013). By comparison,
cholesterol efflux-dependent anti-inflammatory functions of
LXR, which interfere with TLR signaling, have been shown to
broadly interfere with TLR signaling and inflammatory gene acti-




Figure 5. LXR Represses Neutrophil Migration Genes
WT BMDMs were treated for 3 hr with 500 nM T0 before stimulation with 10 ng/mL LPS for 2 hr and harvested for RNA-seq.
(A) Heatmap of all induced or repressed genes at 5% FDR, colored by row-normalized Z score, with extent of induction by LPS indicated on right.
(legend continued on next page)
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Figure 6. LXR Activation Suppresses
Neutrophil Migration In Vivo
Mice were treated with T0 or vehicle before in-
duction of zymosan peritonitis.
(A) Dosing schedule for treatments and harvest of
peritoneal exudates.
(B–D) Total peritoneal exudate cell (B), neutrophil
(C), and macrophage (D) counts at 0, 12, or 24 hr
after zymosan injection. Cell counts were deter-
mined by flow cytometry.
(E) Peritoneal exudate cell mRNA expression at 4 hr
after zymosan injection was measured by qPCR.
(F) Peritoneal exudate leukocyte subsets were
isolated using anti-Ly6G- or anti-F4/80-conjugated
magnetic beads at 4 hr after zymosan injection and
mRNA expression was measured by qPCR.
Mean ± SEM is plotted; n = 4–5 biological repli-
cates. Significance was determined by two-way
ANOVA with Sidak’s post hoc test (B–D) or by
Student’s t test with Benjamini-Hochberg multiple
testing correction (E and F). *p < 0.05, **p < 0.01,
and ***p < 0.001 for individual time point; yp < 0.05,
yyp < 0.01, and yyyp < 0.001 for treatment effect by
2-way ANOVA; #p < 0.05, ##p < 0.01, and ###p <
0.001 for leukocyte subset effect. Data are repre-
sentative of two independent experiments.
See also Figure S4.The combined activities of LXR repression attenuate the
expression of neutrophil cell adhesion and migration genes,
and we observed that LXR activation limits neutrophil recruit-
ment during sterile peritonitis. Our data suggest that the cis-(B) PANTHER GO categories enriched in T0-repressed genes (Bonferroni-adjusted p < 0.05).
(C) PANTHER GO categories enriched in T0-induced genes (Bonferroni-adjusted p < 0.05).
(D and E) Row-normalized Z score for T0-repressed genes in the GO category ‘‘Leukocyte cell-cell adhesion’’
replicates.
See also Table S6.
Cell Reportrepressive function of LXR, by suppress-
ing integrin gene expression, may play a
role in this activity. In addition, we found
that neutrophil expression of cholesterol
efflux transporters is robust and strongly
stimulated by T0. A role for cholesterol
efflux in limiting inflammatory migration
of these cells is consistent with previous
reports that ABCA1 activity is associated
with decreased migration in macrophages
(Zhu et al., 2012). Thus, it is likely that
both cis-repression and cholesterol efflux
contribute to the efficacy of T0 in the sup-
pression of neutrophilic inflammation.
In atherosclerosis, LXR agonists are
protective even in the absence of choles-
terol efflux transporters, highlighting the
importance of the dual functions of LXR
in metabolism and inflammatory gene
control (Kappus et al., 2014). The repres-
sion of neutrophil migration genes byLXR agonists may be particularly important in this context, as
mice with cholesterol efflux transporter deficiency in myeloid
cells have prominent neutrophil accumulation and neutrophil
extracellular trap formation in lesions (Westerterp et al., 2018).(D) or ‘‘Granulocyte chemotaxis’’ (E). n = 3 biological
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Although LXR agonists have hepatotoxic effects, targetingmeta-
bolic and inflammatory functions of neutrophils or macrophages
by activating LXR in these cells specifically remains a promising
therapeutic strategy for the treatment of atherosclerosis.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Wild-type C57BL/6J mice were obtained from The Jackson Laboratory (stock #000664). LXR KO (Nr1h3/ Nr1h2/) mice were
generated as described previously (Alberti et al., 2001) and were backcrossed into the C57BL/6J background for at least 10 gener-
ations.Myd88/mice were obtained from The Jackson Laboratory (stock #009088) andwere backcrossed into the C57BL/6J back-
ground for at least 10 generations. LysMCre Abca1fl/flAbcg1fl/fl and littermate control Abca1fl/flAbcg1fl/fl mice were generated as
described previously (Westerterp et al., 2013). Lpcat3fl/fl were generated as described previously (Kabir et al., 2016) and crossed
with LysMCre mice from The Jackson Laboratory (stock #004781) to generate mice with myeloid Lpcat3 deficiency and littermate
controls.
All mice were housed at Columbia University Medical Center according to animal welfare guidelines. Animals were kept under spe-
cific pathogen-free conditions with ad libitum access to both food and water. Mice were fed irradiated chow diet (Purina Mills diet
5053). Housing temperatures were kept within a range of 71-73F (21.7-22.8C). Water and cages were autoclaved and cages
were changed once weekly. The health status of the mice wasmonitored using a dirty bedding sentinel program and no health status
issues or changes in immune status were identified. Mice were not used for any procedures prior to bone marrow isolation or peri-
tonitis experiments. Femalemice aged 8-12 weeks (weight 18-25 g) were used for all experiments. For in vivo peritonitis experiments,
age-matchedmice were randomly assigned to treatment or control groups. No inclusion or exclusion criteria were used. All protocols
were approved by the Institutional Animal Care and Use Committee of Columbia University.Cell Reports 25, 3774–3785.e1–e4, December 26, 2018 e2
Primary Cell Culture
For generation of bone marrow-derived macrophages, female mice aged 8-10 weeks were euthanized in accordance with American
Veterinary Association Panel on Euthanasia regulations and bone marrow was isolated from femurs and tibias. Bone marrow cells
were differentiated into macrophages by culture in DMEM 10% FBS, 1% pen-strep supplemented with 20% L-cell conditioned me-
dium in tissue culture treated plates in an incubator set at 37C and 5%CO2. After 7 days, macrophages were fully differentiated and
subjected to a one-day serum deprivation in DMEM, 1% pen-strep supplemented with 4% L-cell conditioned medium to normalize
exposure to serum-derived lipoproteins before treatment with LXR agonist and inflammatory agents as described in Method Details.
METHOD DETAILS
Zymosan Peritonitis
Female mice aged 10-12 weeks were randomly assigned to vehicle or LXR agonist treatment groups. Mice were pre-treated with
10 mg/kg T0901317 (Selleckchem) prepared in 0.9% carboxymethylcellulose solution, or vehicle alone, for 3 days by daily oral
gavage. Twenty-four hours after the 3rd dose, mice were treated once with 10 mg/kg T0901317 prepared as above, or vehicle alone,
by oral gavage 2 hours before intraperitoneal injection of 0.1 mg zymosan (Sigma) in 0.5 mL sterile PBS. At 4, 12, or 24 hours after
zymosan treatment, or without zymosan injection, mice were euthanized in accordance with American Veterinary Association Panel
on Euthanasia regulations. Peritoneal exudates were harvested and cells were stained with anti-F4/80 clone BM8 (eBioscience) and
anti-Ly6G clone 1A8 (BioLegend) for analysis of cell counts by flow cytometry or isolated with anti-F4/80 or anti-Ly6G microbeads
(Miltenyi) for RNA analysis. For blood neutrophil counts, blood was collected by cardiac puncture and treated with RBC lysis buffer
(Biolegend). Blood cells were stained with anti-CD115 clone AFS98 (Thermo) and anti-Gr1 clone RB6-8C5 (BD Biosciences) for anal-
ysis of cell counts by flow cytometry. Exudate protein content was measured by bicinchoninic acid (BCA) assay (Pierce). For peri-
tonitis experiments, data is representative of two independent experiments and 4-6 mice were used for each condition, as indicated
in the figure legends.
BMDM Treatment and Stimulation
For LXR agonist treatment and inflammatory stimulation of macrophages, BMDMwere treated with LXR agonist T0901317 (Selleck-
chem) at a concentration of 500 nM or DMSO vehicle alone at a 1:10,000 dilution in serum-free medium with 4% L-cell conditioned
medium for 3 hours. After this treatment period, macrophageswere harvested directly for transposase-accessible DNA isolation from
unstimulated cells or stimulated with 10 ng/mL LPS (Cell Signaling) added directly to agonist-containing medium for 2 hours before
transposase-accessible DNA or RNA isolation. For knockdown experiments, macrophages were differentiated as described above
and treated on day 7 with 100 nM SMARTpool siRNA (Dharmacon) against Scd2 or control non-targeting siRNA complexed with
Lipofectamine RNAiMAX (Thermo) in OptiMEM medium (Thermo) for 24 hours. After this period, Optimem was aspirated and re-
placed with DMEM, 1% pen-strep supplemented with 4% L-cell supernatant for one additional day. On day 9, macrophages
were treated with LXR agonist T0901317 at 500 nM for 3 hours and stimulated with 10 ng/mL LPS for 2 hours. For MAPK inhibitor
experiments, macrophages were treated with 10 mM PD0325901 (Sigma) and 1 mM BIRB0796 (AXON Medchem) as described
(Tong et al., 2016) starting at the same time as treatment with T0901317 at 500 nM for 3 hours before stimulation with 10 ng/mL
LPS for 2 hours. For MERTK antibody neutralization experiments, anti-Mer blocking antibody AF591 (R&D Systems) was added
3 hours prior to treatment with T0901317 at 500 nM for 3 hours and stimulated with 10 ng/mL LPS for 2 hours. For each BMDM stim-
ulation experiment, data is representative of two independent experiments and 3-4 independently differentiated macrophage cul-
tures were used for each condition, as indicated in the figure legends.
Gene Expression Analysis
Macrophages were washed twice with cold PBS and lysed in RNA lysis buffer (QIAGEN or Zymo Research). RNA was isolated using
RNeasy kits (QIAGEN) or RNA MiniPrep kits (Zymo Research). cDNA was prepared using first strand synthesis kits (Thermo) and
qPCR was performed on an ABI StepOnePlus machine with SYBR reagents (Thermo). The following primers were used for qPCR
analyses: Cox2-F: AACCGCATTGCCTCTGAAT; Cox2-R: CATGTTCCAGGAGGATGGAG (Nasser et al., 2012); Il1b-F: GCAACTG
TTCCTGAACTCAACT; Il1b-R: ATCTTTTGGGGTCCGTCAACT (Huang et al., 2011); Abca1-F: CAGCTTCCATCCTCCTTGTC;
Abca1-R: CCACATCCACAACTGTCTGG (Murphy et al., 2013); Abcg1-F: GTACCATGACATCGCTGGTG; Abcg1-R: AGCCGTA
GATGGACAGGATG (Murphy et al., 2013); Itgb2-F: CCCAGGAATGCACCAAGTACA; Itgb2-R: CAGTGAAGTTCAGCTTCTGGCA
(generated for this paper).
ATAC-seq Experimental Preparation
Sampleswere prepared for ATAC-seq essentially as described previously (Buenrostro et al., 2013).Macrophageswerewashed twice
in cold PBS, scraped in cold PBS, and counted using a hemocytometer. Based on this count, 50,000 cells were aliquoted and pel-
leted by centrifugation. Cell pellets were washed once with 50 mL cold PBS on ice before lysis in 50 mL hypotonic lysis buffer (10 mM
Tris-HCl pH 7.5, 10 mM NaCl, 3 mMMgCl2, 0.1% IGEPAL CA-630) over the course of a 10 minute spin at 4C. Pelleted nuclei were
resuspended in 50 uL transposition reaction mix with 3 uL Nextera transposase per sample (Illumina). The reaction was stopped
with 0.1% SDS and transposase-accessible DNA was isolated using AMPure XP beads (Beckman-Coulter). Accessible DNA wase3 Cell Reports 25, 3774–3785.e1–e4, December 26, 2018
amplified by PCR for 5 cycles, assessed for yield by qPCR, and amplified for an additional 7 cycles. Libraries were sequenced on a
NextSeq 500 (Illumina).
ATAC-seq Data Processing
ATAC data from each sample was aligned using Bowtie2 (Langmead and Salzberg, 2012) after adaptor trimming using cutadapt
(Martin, 2011) and PCR duplicates were removed using samtools (Li et al., 2009). Quadruplicate samples for each condition were
used for peak calling by MACS2 (Zhang et al., 2008) with the parameters -q 0.001–nomodel–shift 88–extsize 177 to set an FDR
threshold of 0.1% and account for average insert size. Coverage tracks were created using deeptools (Ramı´rez et al., 2014) using
reads per genomic content (RPGC) normalization and visualized in Integrative Genomics Viewer (Thorvaldsdo´ttir et al., 2013). To limit
ATAC peak identification to transposase-accessible enhancers and exclude other accessible loci, ATAC peaks were filtered accord-
ing to correspondence with H3K27ac- or H3K4me2-marked macrophage enhancers in resting or stimulated primary macrophages
identified previously (Oishi et al., 2017). Enhancer overlap, overlap between conditions, and nearest gene annotation were performed
using bedtools (Quinlan and Hall, 2010). Gene Ontology analysis of nearest genes for each enhancer set was performed using the
PANTHER database (Thomas et al., 2003) and sequence motif analysis was performed using HOMER (Heinz et al., 2010). Motif anal-
ysis for T0-closed and LPS-opened enhancers was performed using the full set of unstimulatedmacrophage enhancers as sequence
background, while motif analysis for T0-closed-in-LPS enhancers was performed using the full set of LPS-stimulated enhancers as
sequence background. Enhancers were aligned to LXR ChIP-seq data from Oishi et al., 2017 using deeptools (Ramı´rez et al., 2014),
and enhancer-TSS distances were computed using custom scripts deposited at https://github.com/dgt2109/bio-script.
RNA-seq
For RNA-seq, macrophages were washed twice with cold PBS and lysed in TRIzol reagent (Thermo). RNA was isolated from the
aqueous phase using RNeasy kits (QIAGEN). RNA with RIN > 8 was subjected to poly-dT pulldown using magnetic beads (NEB)
before preparation for RNA-seq using RNA Ultra kits (NEB). Libraries were sequenced on a NextSeq 500 (Illumina) and reads
were aligned to the mm10 transcriptome using HISAT2 (Kim et al., 2015) after adaptor trimming using cutadapt (Martin, 2011). Reads
counts per gene for RefSeq genes were computed using featureCounts (Liao et al., 2014). Counts were normalized to reads per kilo-
base per million (RPKM) and processed for pairwise differential expression analysis of selected conditions using DESeq2 (Love et al.,
2014) with a False Discovery Rate (FDR)-adjusted p value cutoff of 0.05. Gene Ontology analysis was performed using the PANTHER
database (Thomas et al., 2003).
Measurement of Phosphatidylcholine Subspecies
Phosphatidylcholine subspecies of BMDM were measured using infusion-based high-resolution mass spectrometry as described
previously (Li et al., 2012) using a Triple TOF 5600 (AB-Sciex). Lipids were extracted using the Bligh/Dyer method (Bligh and Dyer,
1959) after addition of internal standards and data were acquired on a Triple TOF 5600 operated in TOF mode at a resolution of
35,000, electrospray source voltage of 5500 v on the Turbo B spray interface, declustering potential of 100 V, scanning from 100 to
1200Da. Sampleswere infused at20 mL/min in a solution of 4:2:1 isopropanol:methanol:chloroformwith 10mMammonium acetate
with aReliance autosampler (Sparck) operating inpressurized vesselmode.QuantitationwasperformedusingMultiQuant (AB-Sciex).
A window of ± 5 mDa was used to identify PC species. Curves were calculated using 1/X weighting and were applied uniformly.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data are presented as mean ± SEM. In BMDM experiments, sample size (n) represents the number of individually differentiated
primarymacrophage cultures in each experiment. In peritonitis experiments, sample size (n) represents the number of individual mice
in each experiment. The statistical parameters (n, mean, SEM, and statistical tests used) can be found within the figure legends and
figures. For comparisons of 2 datasets, the Student’s t test with Benjamini-Hochberg multiple testing correction was used to deter-
mine significance. For comparison of 3 or 4 datasets, one-way ANOVA with Tukey’s post hoc test was used, except in the case of
time-course data where two-way ANOVAwith Sidak’s post hoc test was used to determine significance. For RNA-seq, gene expres-
sion differences were evaluated by Wald test after linear model fitting using DESeq2 and genes significant at 5% FDR were consid-
ered to be differentially expressed. ATAC-seq peaks were identified using Model-Based Analysis of ChIP-seq 2 (MACS2) software.
Enhancer-gene distance distributions were compared using Kruskal-Wallis nonparametric one-way ANOVAwith Dunn post hoc test.
The criterion for significance was set at p < 0.05. No inclusion or exclusion criteria were used. No statistical method was used to
determine whether the data met assumptions of the statistical approach. Statistical analyses were performed using GraphPad Prism
version 7.0.3 or R software with the indicated packages for sequencing data.
DATA AND SOFTWARE AVAILABILITY
The NCBI GEO accession numbers for high throughput sequencing data reported in this paper are GEO: GSE110002, GSE109997,
and GSE109998. Custom scripts for enhancer-promoter distance calculation are deposited at https://github.com/dgt2109/
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